05/25/22 8:30 AMNasdaq : ABVC low floatABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partnersvia NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has been engaged by Orion BioTech, Inc., aRHEA-AIneutral
05/23/22 7:30 AMNasdaq : ABVC low floatPrestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression MedicinesABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Maurizio Fava and Dr. Thomas Laughren haveRHEA-AIneutral
05/16/22 5:46 PMNasdaq : ABVC low floatABVC Biopharma Reports First Quarter 2022 Financial and Operational ResultsABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the firstRHEA-AIvery positive
05/16/22 3:25 PMNasdaq : ABVC offeringlow floatWallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct OfferingWallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of the purchase and sale of 2,000,000 shares of common stock of ABVC BioPharma, Inc. (Nasdaq: ABVC), and warrants toRHEA-AIneutral
05/13/22 8:30 AMNasdaq : ABVC low floatABVC BioPharma Engages the FreeMind Group to Support Grant Fundingvia NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has engaged the FreeMind Group to help ABVC exploreRHEA-AIvery positive
05/12/22 9:00 AMNasdaq : ABVC offeringlow floatWallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct OfferingWallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical-stage biopharmaceutical company, has entered into securities purchase agreements withRHEA-AIneutral
05/12/22 8:30 AMNasdaq : ABVC offeringlow floatABVC BioPharma, Inc. Announces $4.22 Million Registered Direct OfferingABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase agreements with certain institutional investors for the issuance and sale of 2,000,000 shares of commonRHEA-AIneutral
05/10/22 8:30 AMNasdaq : ABVC clinical triallow floatABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treatedvia NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the first subject began treatment at the ChengRHEA-AIneutral
05/05/22 8:30 AMNasdaq : ABVC low floatABVC BioPharma Announces Streamlined Vitargus® Manufacturing ProcessABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced thatRHEA-AIvery positive
05/03/22 8:30 AMNasdaq : ABVC low floatABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMedvia NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the companyRHEA-AIvery positive